Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeThese findings depend on the use of the standardised mean difference
Posted by plosmedicine on 31 Mar 2009 at 00:22 GMT
Author: PJ Leonard
E-mail: coroebus@yahoo.com
Submitted Date: March 03, 2008
Published Date: March 4, 2008
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.
Although it is admirable that Kirsch et al have been able to obtain the complete pre-licencing data for these antidepressants, their results, and thus conclusions, are dependent on the use of a specific statistical measure, the standardised mean difference (SMD).
If the weighted mean difference is used (an equally, or more valid approach given that all studies utilised the same outcome measure, namely the HRSD) effect sizes expressed in HRSD scores are larger than reported in this study (2.8 vs 1.8), and paroxetine and venlafaxine reach the NICE criteria for 'clinical significance' (HRSD change > 3):
http://pyjamasinbananas.b...
Similarly, regression on baseline HRSD scores against HRSD change scores reaches 'clinical significance' at lower scores than found by Kirsch et al (26 vs 28) and minimal decrease in placebo responsiveness with increasing baseline severity:
http://pyjamasinbananas.b...
It is unfortunate that this study has received so much uncritical media coverage when the results are more nuanced than they first appear.